 |
|
|
| |
Pharmacokinetics of Selonsertib, GS-9674,
and/or GS-0976 in Combination in Healthy Subjects
|
| |
| |
Reported by Jules Levin
EASL 2017
International Liver Congress™, 19-23 April 2017, Amsterdam, the Netherlands
Cara H. Nelson, Brian J. Kirby, Na Lu, Bryan McColgan, C. Stephen Djedjos, Robert P. Myers, Jennifer Cuvin, Ann Qin, Anita Mathias
Gilead Sciences, Inc., Foster City, California, USA
Evaluation of the Safety and Pharmacokinetics of the Oral, Nonsteroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers - (11/29/16)
FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASH - (12/02/16)
GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial - (11/21/16)
Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) - (10/21/16)
References
1. Loomba R, et al. AASLD 2016, abstr LB-3; 2. Djedjos CS, et al. AASLD 2016, poster 1077;
3. Westlin WF. EASL 2016, oral PS108; 4. Nelson CH, et al. EASL 2017, poster THU-343
|
| |
|
|
|
|
|
